Skip to main content

Table 1 Methylation status and two-year survival of patients following surgery.

From: Qualitative analysis of Adenomatous Polyposis Coli promoter: Hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker

Tumor differentiation status * Total Survival rate Methylated tumors Survival rate Unmethylated tumors Survival rate
Poor 32 24 13 (40.6%) 8 (61%) 19 (59%) 16 (84%)
Moderate 5 4 2 (40%) 2 (40%) 3 (60%) 2 (67%)
well 8 4 5 (62%) 1 (20%) 3 (37.5%) 3 (100%)
Total 45 32 20 (44%) 11 (55%) 25 (56%) 21 (84%)
  1. *Differentiation classification according to the WHO criteria (World Health Organization, 1977)